Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Concentra Group Holdings Parent, Inc. (CON)
A forensic read on Concentra Group Holdings Parent, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
2.9
Distress distance
Clean
Earnings quality
4
Forensic signals
22.1
P / E (ttm)
42.3%
ROE
$4.3B
Market cap
0.81%
Dividend yield
13.9%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Concentra Group Holdings Parent, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 2.9, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+12.3%/yr
FY2024–FY2025
Share-count dilution.Diluted share count changed +12% over the last 1 year to FY2025 (+12.3%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~12.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~11%.
+18.3%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +18.3% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by receivables up +18% against revenue +14%. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 6% of net operating assets, diverging from the balance-sheet accrual read.
10.5%
FY2025
Return on invested capital.Return on invested capital is 10.5% in the latest fiscal year and steady — around its ~10% cost of capital, so growth is roughly value-neutral.
0.5% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 0.5% of revenue and 5% of free cash flow in FY2025 — about $0.08 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 12.3% a year, small enough that totals and per-share results tell the same story.
Key fundamentals
Latest Revenue$2.16B
Revenue Growth YoY+13.9%
Net Margin7.7%
Free Cash Flow$197.1M
Return on Equity42.3%
Debt / Equity4.00x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Concentra Group Holdings Parent, Inc.'s actual 10-K/10-Q/8-K filings?